Good morning, everyone, and welcome to Sleep Cycle's Q1 2026 Earnings Call. I'm Erik Jivmark, I'm the CEO, and I'm joined by Elisabeth Hedman, our CFO. So Q1 was a transition quarter.
It was softer on the top line as expected.
But importantly, the strategic shift that we've been communicating is becoming visible. It's becoming visible in our revenue mix and also in the platform we're building.
So today I will cover three things. The strategic moment we're in, then how our market is expanding and how our three growth pillars are progressing. Then I will hand it over to Elisabeth. She will talk through the financials and targets before we open up for a Q&A.
So our mission is unchanged. It is to improve global health by empowering people to take control of their sleep.
And the fact is that sleep is no longer a niche. It's becoming a core pillar of global health.
And this goes across mental health, metabolic, and cardiovascular outcomes.
What is changing now is not our mission. It's how we scale it. We're moving beyond the app stores. So before we discuss Q1, it's very important to understand the foundation we're building from. Sleep Cycle is an authority in sleep. We have over 4 billion nights of sleep data.
We have 2.5 million active users and 82 million installs.
And that combination with data distribution and also reach is extremely difficult to replicate in a single product. And what is important to understand is that this has been built over the years almost entirely organically. So now we're making a shift from passive growth to a more structured, proactive model.
And I like to say that we're taking control of our own destiny.
But before we jump into the shift, what we have built is a highly profitable cash-generating business. Net sales have grown from 182 to 248 million between 2021 and 2025. About 36% compounded growth. At the same time, EBIT margins have expanded to around 26 to 30%. So, what we have is a structurally profitable and very efficient model.
And we're also starting to see the shift. B2B has grown from 2% of our revenue in 2023. And in Q1, it's almost 15%. And all of this with around 35 employees.
So the key point here is we're evolving from a position of strength.
2026 is a deliberate transition year. We are reinvesting into the platform. So, Tech Licensing, Sleep Apnea, and the new growth engines. And from 2027, we expect that to translate into reaccelerated growth but on a much larger market. And the reason why we believe we can capture this market is because sleep is becoming a core pillar of global health.
And this is not a trend.
It's a structural shift. And we see three clear drivers behind this. First of all, sleep has moved from being a nice to have to a core driver of both health and performance.
Secondly, the scale. It's significant. Sleep Apnea alone affects around 1 billion people, and most of them are still undiagnosed.
And third, healthcare is shifting to continuous, passive, and embedded solutions. And that's exactly how our technology is built. So demand is not the issue. Demand is very strong and it's actually growing. The constraint is distribution. And importantly, this growth is not reflected in the App Store dynamics, where currently our category is deprioritized.
So while the market is expanding rapidly, much of that expansion is happening outside the channels where we have historically operated. So up until now, we have operated in a market of roughly 1.7 billion. SEK. And we've had roughly 15% of that market. And that is where we built a very strong and profitable position.
And what is changing now? It's not our technology.
It's where that technology can be applied. So by expanding into sleep apnea and also tech licensing, we increase our addressable market to roughly 45 billion SEK. So effectively what we have is the same core technology but significantly larger markets. That is what this evolution is about.
And these estimates that I show here, it's based on the analysis made by Arkwright, also combined with some some public sources and an internal assessment that we have made. So the strategy going forward is built on three pillars.
And they are all powered by the same platform. First, we have the Sleep Cycle App. It's our cash generating consumer engine.
Secondly, it's sleep apnea.
I would say that's our largest upside opportunity. We are right now in clinical validation. We have 150,000 people who have already registered. And we see a tremendous B2B potential. And finally, we have tech licensing.
And tech licensing is about turning our technology into a scalable B2B platform via SDK across wearables, pharma, and also digital health.
So the key point in this is all three are built on the same core technology and the same data. And that gives us a lot of things. It gives us high scalability. It gives us low incremental cost and also a structurally stronger revenue model over time.
But let's go through each of these pillars a bit more in detail so you know where we are if we start with the consumer app. It remains very strong and it's an important part of the business, and we're doing a lot of things to optimize it. So in Q1, we have increased prices by 15% on iOS. And you see that on the ARPU already, we have improved onboarding. We have been lifting first night activation to 45%, meaning that we have more users that can experience our product and hence increase the pool that we can try to convert.
And in the long run, of course, more users do not only generate data, but they also can be a pool of customers that we can reach with our Sleep Apnea offering and also having a lot of users making us even more relevant for B2B partners.
We have launched Luma. It's our AI-based sleep coach, which we see improves Day 8 retention, meaning it builds engagement so it improves retention on all days. Day eight is an important day for us due to the trial time that we offer.
We have. And finally, we're ready for a new distribution channel, and we are actively pursuing it. We shared in the report this morning that OpenAI was mentioned. We launched, and we were one of the first in our category to be on ChatGPT.
So the direction is clear.
We're moving from a tracking product, you could say, to a more personalized sleep and health platform.
Then we have the second pillar. It's sleep apnea. I believe it's by far our largest upside opportunity. Around 1 billion people are affected globally, and the majority of them are undiagnosed.
There are existing solutions out there. They are often expensive. They are not scalable because they involve hardware. And our contactless, AI-based detection tool that we are developing is, of course, benchmarked against what is out there and what is already approved.
And what we see is that we reach an 84.5% sensitivity in the test that we're doing internally, meaning that we are comparable to the incumbents. The difference, though, is that we can be delivered at a price point of 100 to 500 SEK versus thousands for traditional Sleep Apnea detection tools.
And the demand signal is already strong. We have more than 150,000 individuals that have registered their interest for their B2C offering. But again, I believe that the greatest potential is in the B2B segment. And we are right now in dialogues with multiple potential B2B partners across this value chain.
So in terms of regulatory path towards this commercial launch, we are progressing well. Our target is to launch in the first half of 2027. And we've taken a very de-risked approach. So what that means is that we're working with specialists to ensure that we have the right alignment with FDA and also the key requirements. We are setting up the required quality systems for the software as a medical device, and these are being put in place right now. And we're doing external audits, and they have confirmed that we are on the right track.
On the study side, development was completed in Q1 for the algorithm, and we have now started validation in Q2, and we are on schedule. So the next steps are that we will do the design freeze in Q2. We will complete the study in September. And then our target is to submit this to FDA in October.
The third pillar is tech licensing. And this is our way of basically scaling the platform beyond our own app. Because through the SDK, what we do is we make our core technology and also the data available to partners across industries. And that gives us access to use cases and also customers that we would not be able to reach ourselves.
But it's also important to understand one thing: the SDK business, or the licensing business, is an entry point.
Many of these partners are also highly relevant for sleep apnea. So the model is quite simple. We start with the licensing and the SDK. We are building the relationship and then over time we will move in with the medical expansion.
So in Q1, we see some early signs of this.
We have some first revenue coming from SDK. We are growing the pipeline across both licensing and the medical application. And we are also finalizing the cough data validation study together with UKHSA, which is a prerequisite ahead of commercial discussions. It's about understanding if the coughing data could work as an early warning signal.
So tech licensing is both a scalable B2B revenue stream, but it's also a strategic gateway into the sleep apnea B2B opportunity. Thank you so much, Eric.